AMIX

Company Overview — What Does Autonomix Medical, Inc. Do?

We are a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Our first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. We calculate sensitivity in units of minimum signal detection voltage in micro volts (uV) time area of the electrode (square millimeters). It is a combined measure that is related to the signal resolving power and spatial resolution of the system. For the BSC Orion, the nearest device on the market, the metrics are 10uV for signal detection levels, and roughly 0.4mm by 0.5mm for the electrode dimensions. For the Autonomix device, the metrics are <1uV for signal detection levels and roughly 0.02mm by 0.03mm for the electrode dimensions. The differences in these metrics result in a calculation of 3,000 times greater sensitivity for the Autonomix device. We believe, if we can recreate these results in clinical trials, this will enable a method of transvascular targeting, treating, and confirming treatment of diseases involving the nervous system throughout the body that is not currently available and may be capable of filling a wide range of unmet medical needs. We are initially developing our technology for patients with pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need a more effective solution. However, we believe our technology constitutes a platform with the potential to address dozens of indications in a range of areas including chronic pain management from all causes, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. Our development efforts can be divided into to two sub parts: sensing and treatment, where sensing is focused on identifying neuronal activity that may be associated with a disorder with enough precision to enable targeted treatment. Our sensing catheter has already been developed sufficiently to demonstrate in animal models successful identification of a signal from a specific nerve before ablation and confirmation of termination of that signal from the treated nerve after ablation. We are now in the process of improving the assembly of this catheter to meet the standards required for human use. In parallel with this effort, we are preparing for a first-in-human demonstration of transvascular ablation to relieve pain associated with pancreatic cancer, with the intent to bring sensing and treatment together in a future pivotal clinical trial to enable the commercial launch of our technology. We are a development stage company and there is no guarantee that the results of any trials will produce positive results or that the results will support our claims. We believe one of the most demanding aspects of our commercialization plan will be scaling up from our existing sensing prototype to a robust commercial version. Today, our sensing device is hand built and includes a combination of hand-crafted and 3D printed parts. We have not yet assembled or tested what will be the commercial version of our proposed device. Even if our proposed device is cleared for commercial use, there is no assurance that we will be able to successfully build such device on a commercial scale. Our principal executive offices are located at 21 Waterway Avenue, Suite 300, The Woodlands, TX. Autonomix Medical, Inc. (AMIX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Lori Bisson, headquartered in THE WOODLANDS, Texas. With a market capitalization of $5M, AMIX is one of the notable companies in the Healthcare sector.

Autonomix Medical, Inc. (AMIX) Stock Rating — Avoid (April 2026)

As of April 2026, Autonomix Medical, Inc. receives a Avoid rating with a composite score of 21.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.AMIX ranks #4,224 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Autonomix Medical, Inc. ranks #756 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AMIX Stock Price and 52-Week Range

Autonomix Medical, Inc. (AMIX) currently trades at $0.37. The stock lost $0.03 (7.7%) in the most recent trading session. The 52-week high for AMIX is $2.82, which means the stock is currently trading -86.9% from its annual peak. The 52-week low is $0.34, putting the stock 8.1% above its annual trough. Recent trading volume was 137K shares, suggesting relatively thin trading activity.

Is AMIX Overvalued or Undervalued? — Valuation Analysis

Autonomix Medical, Inc. (AMIX) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.51x, versus the sector average of 2.75x.

At current multiples, Autonomix Medical, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Autonomix Medical, Inc. Profitability — ROE, Margins, and Quality Score

Autonomix Medical, Inc. (AMIX) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -188.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -158.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AMIX Debt, Balance Sheet, and Financial Health

Autonomix Medical, Inc. has a debt-to-equity ratio of 19.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.18x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $7M.

AMIX has a beta of 0.58, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Autonomix Medical, Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Autonomix Medical, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Autonomix Medical, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.36. Net income for the quarter was $-16M. Operating income came in at $-16M.

In Q3 2026, Autonomix Medical, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.36. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2026, Autonomix Medical, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.38. Net income for the quarter was $-7M. Operating income came in at $-8M.

In FY 2025, Autonomix Medical, Inc. reported revenue of $0 and earnings per share (EPS) of $-6.46. Net income for the quarter was $-11M. Operating income came in at $-12M.

Over the past 8 quarters, Autonomix Medical, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing AMIX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AMIX Dividend Yield and Income Analysis

Autonomix Medical, Inc. (AMIX) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AMIX Momentum and Technical Analysis Profile

Autonomix Medical, Inc. (AMIX) has a momentum factor score of 10/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

AMIX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Autonomix Medical, Inc. (AMIX) ranks #756 out of 838 stocks based on the Blank Capital composite score. This places AMIX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AMIX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AMIX vs S&P 500 (SPY) comparison to assess how Autonomix Medical, Inc. stacks up against the broader market across all factor dimensions.

AMIX Next Earnings Date

No upcoming earnings date has been announced for Autonomix Medical, Inc. (AMIX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AMIX? — Investment Thesis Summary

The quantitative profile for Autonomix Medical, Inc. suggests caution. The quality score of 17/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 10/100, a headwind for near-term performance. High volatility (stability score 32/100) increases portfolio risk.

In summary, Autonomix Medical, Inc. (AMIX) earns a Avoid rating with a composite score of 21.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AMIX stock.

Related Resources for AMIX Investors

Explore more research and tools: AMIX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AMIX head-to-head with peers: AMIX vs AZN, AMIX vs SLGL, AMIX vs VMD.